GIST pipeline
Drugs
Every gastrointestinal stromal tumor program in this file, grouped by class. Open a drug for its studies and the sources behind each figure.
ClassNone selected
All programs shown
17 of 17 programs shown
anti-PD-L1 (with imatinib) 1 drug
- Atezolizumab + ImatinibCentre Leon BerardPhase 2atezolizumab, intravenous. imatinib, oral1 studyanti-PD-L1 (with imatinib)
anti-PD-L1 (with regorafenib) 1 drug
- Envafolimab + RegorafenibPeking UniversityPhase 2envafolimab, subcutaneous. regorafenib, oral1 studyanti-PD-L1 (with regorafenib)
Class not reported 1 drug
- DCC-3009Deciphera PharmaceuticalsPhase 1/2oral1 studyClass not reported
HIF-2 alpha inhibitor 1 drug
- BelzutifanMerckPhase 2oral1 studyHIF-2 alpha inhibitor
HSP90 inhibitor (with imatinib) 1 drug
- Pimitespib + ImatinibTaiho PharmaceuticalPhase 1oral1 studyHSP90 inhibitor (with imatinib)
KIT type I TKI plus type II TKI combination 1 drug
- Bezuclastinib + SunitinibCogent BiosciencesFiledoral1 studyKIT type I TKI plus type II TKI combination
KIT-directed ADC 1 drug
- NN3201 (KIT Antibody-drug Conjugate, MMAE)Novelty NobilityPhase 1intravenous1 studyKIT-directed ADC
KIT/PDGFRA TKI (type II) 1 drug
KIT/PDGFRA type I TKI 1 drug
- AvapritinibAyvakitBlueprint MedicinesApprovedoral2 studiesKIT/PDGFRA type I TKI
menin inhibitor (with imatinib) 1 drug
- Ziftomenib + ImatinibKura OncologyPhase 1Route n/r1 studymenin inhibitor (with imatinib)
multi-kinase TKI 2 drugs
- Olverembatinib (HQP1351)Ascentage PharmaPhase 3oral2 studiesmulti-kinase TKI
- RegorafenibStivargaBayerApprovedoral1 studymulti-kinase TKI
multi-kinase TKI (type II) 1 drug
selective KIT TKI 2 drugs
- NB003Ningbo Newbay Technology DevelopmentPhase 2/3oral2 studiesselective KIT TKI
- Velzatinib (IDRX-42, GSK6042981)GSKPhase 3oral3 studiesselective KIT TKI
switch-control KIT/PDGFRA TKI 1 drug
- RipretinibQinlockDeciphera PharmaceuticalsApprovedoral3 studiesswitch-control KIT/PDGFRA TKI
VEGFR2 TKI (with paclitaxel) 1 drug
- Rivoceranib + PaclitaxelAsan Medical CenterPhase 2Route n/r1 studyVEGFR2 TKI (with paclitaxel)